Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: A possible role of α1-adrenoceptors

European Neuropsychopharmacology

Volumn 19, Issue 12, 2009, Pages 861-867

  Tanibuchi, Yuko ^a,b   Fujita, Yuko ^a   Kohno, Mami ^a   Ishima, Tamaki ^a   Takatsu, Yuto ^a   Iyo, Masaomi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

1 adrenoceptors; Cognition; Glutamate; NMDA receptor; Schizophrenia

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; PHENCYCLIDINE; PRAZOSIN; QUETIAPINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DENSITY; TREATMENT DURATION; WESTERN BLOTTING;

ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED ICR; PHENCYCLIDINE; PRAZOSIN; RECEPTORS, ADRENERGIC, ALPHA-1; TIME FACTORS;

EID: 70350408714     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.07.005     Document Type: Article

References (51)

1. 1-adrenergic receptors. Neuropsychopharmacol. 31 (2006) 2150-2161
2. Arnsten A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 174 (2004) 25-31
3. 1-noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry 45 (1999) 26-31
4. Bakshi V.P., and Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology (Berl) 122 (1995) 198-201
5. 1-noradrenergic antagonist. J. Pharmacol. Exp. Ther. 283 (1997) 666-674
6. 1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience 92 (1999) 113-121
7. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
8. Baldessarini R.J., Huston-Lyons D., Campbell A., Marsh E., and Cohen B.M. Do central antiadrenergic actions contribute to the atypical properties of clozapine?. Br. J. Psychiatry 17 Suppl. (1992) 12-16
9. 1-adrenoceptor mediation in the prefrontal cortex. Biol. Psychiatry 46 (1999) 1266-1274
10. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47 (1990) 181-188
11. 1A/B adrenoceptor subtype selectivity in the rat. Eur. Neuropsychopharmacol. 15 (2005) 231-234
12. 1-adrenoceptor stimulation in rats. Neuropharmacol. 37 (1998) 401-404
13. 1-adrenergic receptor in schizophrenia. Neurosci. Lett. 401 (2006) 248-251
14. 2 receptors: implications for drug mechanisms of action. Life Sci. 39 (1986) 2571-2580
15. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174 (2004) 32-38
16. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49 (1992) 538-544
17. Freedman R. Schizophrenia. N. Engl. J. Med. 349 (2003) 1738-1749
18. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S., Kern R.S., Kraemer H., Stover E., Weinberger D.R., Zalcman S., and Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56 (2004) 301-307
19. Grenhoff J., and Svensson T.H. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur. J. Pharmacol. 233 (1993) 79-84
20. Gründer G., Hippius H., and Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8 (2009) 197-202
21. 1A receptors. Eur. Neuropsychopharmacol. 18 (2008) 448-454
22. Hashimoto K., Okamura N., Shimizu E., and Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem. - CNS Agents 4 (2004) 147-154
23. Hashimoto K., Fujita Y., Shimizu E., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 519 (2005) 114-117
24. Hashimoto K., Shimizu E., and Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia. Curr. Psychiatry Rev. 1 (2005) 151-163
25. Hashimoto K., Fujita Y., Ishima T., Hagiwara H., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors. Eur. J. Pharmacol. 553 (2006) 191-195
26. Hashimoto K., Fujita Y., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuro-psychopharmacol. 32 (2007) 514-521
27. Hashimoto K., Fujita Y., Ishima T., Chaki S., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine. Eur. Neuropsychopharmacol. 18 (2008) 414-421
28. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., Tsukada H., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 63 (2008) 92-97
29. He J., Xu H., Yang Y., Rajakumar D., Li X., and Li X.M. The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav. Brain Res. 168 (2006) 236-242
30. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
31. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuro-psychopharmacol. 20 (1999) 201-225
32. 2 receptor occupancy. Arch. Gen. Psychiatry 57 (2000) 553-559
33. Keating G.M., and Robinson D.M. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 67 (2007) 1077-1095
34. 1-receptor up-regulation. J. Neural. Transm. 107 (2000) 1413-1426
35. 1B-adrenoceptor. Eur. Neuropsychopharmacol. 10 (2000) 423-427
36. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., Abi-Saab W., and Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7 (1999) 125-143
37. 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res. 460 (1988) 398-401
38. Leysen J.E., Commeren W., and Shotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane J.M., Möller H.J., and Awouters F. (Eds). Serotonin in Antipsychotic Treatment - Mechanisms and Clinical Practice (1996), Marcel Dekker, Inc., New York 51-75
39. 1-adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol. Psychiatry 46 (1999) 1259-1265
40. 1-adrenocepror antagonism. Eur. Neuropsychopharmacol. 10 (2000) 245-253
41. Mathé J.M., Nomikos G.G., Hildebrand B.E., Hertel P., and Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309 (1996) 1-11
42. Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13 (2008) 27-35
43. Peroutka S.J., and Snyder S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 137 (1980) 1518-1522
44. Ramos B.P., and Arnsten A.F. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol. Ther. 113 (2007) 523-536
45. Richelson E., and Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. 68 (2000) 29-39
46. 2A-receptors. Br. J. Pharmacol. 135 (2002) 65-78
47. Spreng M., Cotecchia S., and Schenk F. A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol. Learn. Mem. 75 (2001) 214-229
48. Svensson T.H. α-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1145-1158
49. Volk D.W., and Lewis D.A. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol. Behav. 77 (2002) 501-505
50. 2 receptor antagonist raclopride in rats. J. Neural Transm. 107 (2000) 1229-1238
51. Xu H., Qing H., Lu W., Keegan D., Richardson J.S., Chlan-Fourney J., and Li X.M. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 321 (2002) 65-68